

IN THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1- 23(canceled).

24 (currently amended): A pharmaceutical composition comprising:  
a corticosteroid[[],];  
a hydrofluoroalkane propellant which comprises at least one member selected from the group consisting of 1,1,1,2 –tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane, and mixtures thereof;[],]  
ethanol; a cosolvent; and

an antioxidant,

wherein said composition is in the form of a solution and said antioxidant is present in an amount of 0.2 % to 20% by weight, based on the weight of said composition.

Claim 25 (previously presented): The pharmaceutical composition of claim 24, wherein said antioxidant is ascorbyl palmitate.

Claim 26 (previously presented): The pharmaceutical composition of claim 24, wherein said antioxidant is tocopherol.

Claim 27 (previously presented): The pharmaceutical composition of claim 24, wherein said antioxidant is selected from the group consisting of ascorbic acid, ascorbyl

palmitate, butylated hydroxytoluene, butylated hydroxyanisole, and tocopherol.

Claim 28 (previously presented): The pharmaceutical composition of claim 24, wherein said corticosteroid is selected from the group consisting of flunisolide and beclomethasone dipropionate.

Claims 29-31 (canceled).

Claim 32 (currently amended): A pressurized metered dose inhaler comprising a container equipped with a metering valve and containing a pressurized aerosol comprising:

a corticosteroid[[],];

a hydrofluoroalkane propellant which comprises at least one member selected from the group consisting of 1,1,1,2 –tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane, and mixtures thereof;[[],]]

ethanol; a cosolvent, and

an antioxidant,

wherein said composition is in the form of a solution and said antioxidant is present in an amount of 0.2 % to 20% by weight, based on the weight of the composition.

Claim 33 (previously presented): The pressurized metered dose inhaler according to claim 32, wherein said corticosteroid is selected from the group consisting of flunisolide and beclomethasone dipropionate.

Claims 34-36 (canceled).

Claim 37 (previously presented): The pressurized metered dose inhaler according to claim 32, wherein said antioxidant is ascorbyl palmitate.

Claim 38 (previously presented): The pressurized metered dose inhaler according to claim 32, wherein said antioxidant is tocopherol.

Claim 39 (currently amended): A method for the treatment of a bronchial disorder comprising administering a pharmaceutical aerosol composition comprising:

a corticosteroid[[],];

a hydrofluoroalkane propellant which comprises at least one member selected from the group consisting of 1,1,1,2 –tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane, and mixtures thereof;[],]

ethanol; a cosolvent; and

an antioxidant,

wherein said composition is in the form of a solution and said antioxidant is present in an amount of 0.2 % to 20% by weight, based on the weight of the composition.

Claim 40 (previously presented): The method according to claim 39, wherein said corticosteroid is selected from the group consisting of flunisolide and beclomethasone dipropionate.

Claims 41-43 (canceled).

Claim 44 (previously presented): The method according to claim 39, wherein said antioxidant is ascorbyl palmitate.

Claim 45 (previously presented): The method according to claim 39, wherein said antioxidant is tocopherol.

Claim 46 (previously presented): The pharmaceutical composition of claim 24, wherein said antioxidant is present in an amount of 1% to 2% by weight, based on the weight of the composition.

Claim 47 (previously presented): The pressurized metered dose inhaler of claim 32, wherein said antioxidant is present in an amount of 1% to 2% by weight, based on the weight of the composition.

Claim 48 (previously presented): The method according to claim 39, wherein said antioxidant is present in an amount of 1% to 2% by weight, based on the weight of the composition.